Docetaxel rechallenge linked to longer survival than cabazitaxel, study suggests

A common clinical question for medical oncologists treating metastatic castration-resistant prostate cancer is, should patients who previously received docetaxel and progress on it, reuse docetaxel or switch to cabazitaxel when another taxane is needed? Findings from a new study published in JAMA Network Open give more insight into the question.